High-throughput drug screening has shown that BRD4 inhibitors can downregulate TCF4 and disrupt the BPDCN-specific transcription network controlled by TCF4-dependent super enhancers, leading to the apoptosis of BPDCN cells.[34] Emadali et al[29] found that the BRD4 inhibitor, JQ1 can reduce the overexpression of the long-chain non-coding RNA gene (linc-RNA-3q) in BPDCN cells, which is associated with the programmed regulation and G1/S transition of leukemia stem cells. This evidence concerns the gene TCF4 and CD4+/CD56+ hematodermic neoplasm.